TACROLIMUS
PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
BIONPHARMA INC.
Indication
Prevention of liver transplant rejection
Prevention of liver transplant rejection refers to the therapeutic maintenance of immune tolerance to inhibit the host immune system from recognizing and destroying an allogeneic donor liver. Read more about Prevention of liver transplant rejection
119 drugs 71 manufacturers
Drugs that treat it
Common Prevention of liver transplant rejection therapies.
MYCOPHENOLATE MOFETIL
IMMUNOSUPPRESSIVE INOSINE MONOPHOSPHATE DEHYDROGENASE INHIB.·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+2
STRIDES PHARMA
MYCOPHENOLATE MOFETIL
IMMUNOSUPPRESSIVE INOSINE MONOPHOSPHATE DEHYDROGENASE INHIB.·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+2
STRIDES PHARMA
TACROLIMUS
IMMUNOSUPPRESSANTS - CALCINEURIN INHIBITORS·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+3
STRIDES PHARMA
MYCOPHENOLATE MOFETIL (mycophenolate mofetil HCl)
IMMUNOSUPPRESSIVE INOSINE MONOPHOSPHATE DEHYDROGENASE INHIB.·PREVENTION OF KIDNEY TRANSPLANT REJECTION·+2
PAR HEALTH USA,
CYCLOSPORINE MODIFIED (cyclosporine, modified)
SEVERE RECALCITRANT PSORIASIS·+4
ACTAVIS/MAYNE P
CYCLOSPORINE
PREVENTION OF KIDNEY TRANSPLANT REJECTION·+2
L Perrigo Company
MYCOPHENOLATE MOFETIL (mycophenolate mofetil HCl)
PREVENTION OF KIDNEY TRANSPLANT REJECTION·+2
AKORN INC.
MYCOPHENOLATE MOFETIL
PREVENTION OF KIDNEY TRANSPLANT REJECTION·+2
VISTAPHARM
Filter & compare in the drug finder →Opens the drug finder with Prevention of liver transplant rejection preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrevention of liver transplant rejection refers to the therapeutic maintenance of immune tolerance to inhibit the host immune system from recognizing and destroying an allogeneic donor liver.
This clinical management is essential in both adult and pediatric liver allograft recipients.
Pathophysiologically, rejection occurs when recipient T lymphocytes and donor-specific antibodies target foreign major histocompatibility complex antigens, leading to acute cellular or antibody-mediated inflammation of the portal triads, bile ducts, and vascular endothelium, or progressive chronic ductopenia and arteriopathy.
Prophylactic immunosuppression mitigates these destructive immune pathways to prevent graft dysfunction and ensure long-term allograft survival.
- nih.gov
Prevention of liver transplant rejection refers to the therapeutic maintenance of immune tolerance to inhibit the host immune system from recognizing and destroying an allogeneic donor liver Pathophysiologically, rejection occurs when recipient T lymphocytes and donor-specific antibodies target foreign major histocompatibility complex antigens, leading to acute cellular or antibody-mediated inflammation of the portal triads, bile ducts, and vascular endothelium, or progressive chronic ductopenia...
- nih.gov
Prevention of liver transplant rejection refers to the therapeutic maintenance of immune tolerance to inhibit the host immune system from recognizing and destroying an allogeneic donor liver Prophylactic immunosuppression mitigates these destructive immune pathways to prevent graft dysfunction and ensure long-term allograft survival
- fda.gov
This clinical management is essential in both adult and pediatric liver allograft recipients
- starzlnetwork.org
This clinical management is essential in both adult and pediatric liver allograft recipients
- nih.gov
Pathophysiologically, rejection occurs when recipient T lymphocytes and donor-specific antibodies target foreign major histocompatibility complex antigens, leading to acute cellular or antibody-mediated inflammation of the portal triads, bile ducts, and vascular endothelium, or progressive chronic ductopenia and arteriopathy
- nih.gov
Pathophysiologically, rejection occurs when recipient T lymphocytes and donor-specific antibodies target foreign major histocompatibility complex antigens, leading to acute cellular or antibody-mediated inflammation of the portal triads, bile ducts, and vascular endothelium, or progressive chronic ductopenia and arteriopathy
- aasld.org
Prophylactic immunosuppression mitigates these destructive immune pathways to prevent graft dysfunction and ensure long-term allograft survival
Personalize your experience
Follow Prevention of liver transplant rejection and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.